TDM-105795
TDM-105795 is in Phase 2 for androgenetic alopecia, developed by TechnoDerma Medicines.
A topical thyroid hormone receptor agonist — an unusual and largely untried lever.
- Developed by
- TechnoDerma Medicines
- Current phase
- Phase 2
- Mechanism
- Thyroid hormone receptor
- Partners
- Cutia Therapeutics
- Indications
- Androgenetic alopecia
- Also known as
- TDM105795, CU-40101
- Last public activity
- November 2025
- Copy last reviewed
- August 2026
- Record confidence
- Medium
Tests whether it works, at what dose, in a few hundred people.
Stimulates thyroid hormone receptors in the follicle, which regulate its growth cycle.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Development history
- Phase 1Phase 2
First Phase 2 trial on record: NCT05802173 — Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
ClinicalTrials.gov ↗ - Phase 1
First Phase 1 trial on record: NCT04913519 — A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
Technoderma Medicines Inc. · n=71 · March 2023
A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects
Cutia Therapeutics（Wuxi）Co.,Ltd · n=80 · August 2022
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
Technoderma Medicines Inc. · n=32 · February 2022
A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)
Technoderma Medicines Inc. · n=30 · April 2021
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia — ClinicalTrials.gov
- Technoderma Medicines Phase 2 clinical trial of TDM-105795 demonstrates hair growth in androgenetic alopecia — Company release, February 2024
- NCT05802173 study protocol: TDM-105795 is a thyroid hormone receptor-beta agonist developed as a topical drug to promote hair growth — ClinicalTrials.gov, November 2022
Cite this page
Hair Pipeline, "TDM-105795 — development record", hairpipeline.com/pipeline/tdm-105795